PCSK9 inhibition and risk of diabetes: should we worry?
S Carugo, CR Sirtori, A Corsini, L Tokgozoglu… - Current Atherosclerosis …, 2022 - Springer
Abstract Purpose of Review Since the clinical benefit of proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors occurs in a setting of reducing low-density …
subtilisin/kexin type 9 (PCSK9) inhibitors occurs in a setting of reducing low-density …
Sex difference in circulating PCSK9 and its clinical implications
F Jia, SF Fei, DB Tong, C Xue, JJ Li - Frontiers in pharmacology, 2022 - frontiersin.org
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a proprotein convertase that
increases plasma low-density lipoprotein cholesterol (LDL-C) levels by triggering the …
increases plasma low-density lipoprotein cholesterol (LDL-C) levels by triggering the …
Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without …
L Song, X Zhao, R Chen, J Li, J Zhou, C Liu… - Cardiovascular …, 2022 - Springer
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been shown to be
predictive of cardiovascular outcomes in stable coronary artery disease with diabetes. We …
predictive of cardiovascular outcomes in stable coronary artery disease with diabetes. We …
[HTML][HTML] Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study
Background and aims Proprotein convertase subtilisin/kexin type 9 (PCSK9) is one of the
key regulators of low-density lipoprotein cholesterol plasma levels. Circulating PCSK9 …
key regulators of low-density lipoprotein cholesterol plasma levels. Circulating PCSK9 …
Depression and cardiovascular risk—association among Beck Depression Inventory, PCSK9 levels and insulin resistance
C Macchi, C Favero, A Ceresa, L Vigna… - Cardiovascular …, 2020 - Springer
Background Depression and cardiovascular disease (CVD) are among the most common
causes of disability in high-income countries, depression being associated with a 30 …
causes of disability in high-income countries, depression being associated with a 30 …
Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes
Y Tang, SL Li, JH Hu, KJ Sun, LL Liu, DY Xu - Cardiovascular Diabetology, 2020 - Springer
The proprotein convertase subtilisin/kexin type 9 (PCSK9) acts via a canonical pathway to
regulate circulating low-density lipoprotein-cholesterol (LDL-C) via degradation of the LDL …
regulate circulating low-density lipoprotein-cholesterol (LDL-C) via degradation of the LDL …
Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function
Abstract Background and aims Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) is an
endogenous inhibitor of the LDL receptor (LDLR). Mendelian randomization studies suggest …
endogenous inhibitor of the LDL receptor (LDLR). Mendelian randomization studies suggest …
Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes
Background The identification of circulating biomarkers associated with the risk of type 2
diabetes (T2D) is useful for improving the current prevention strategies in the most at-risk …
diabetes (T2D) is useful for improving the current prevention strategies in the most at-risk …
PCSK9 inhibition and cholesterol homeostasis in insulin producing β-cells
G Päth, N Perakakis, CS Mantzoros… - Lipids in Health and …, 2022 - Springer
Low-density lipoprotein cholesterol (LDL-C) plays a central role in the pathology of
atherosclerotic cardiovascular disease. For decades, the gold standard for LDL-C lowering …
atherosclerotic cardiovascular disease. For decades, the gold standard for LDL-C lowering …
Plasma level of ATPase inhibitory factor 1 (IF1) is associated with type 2 diabetes risk in humans: A prospective cohort study
Aim Mitochondrial dysfunction is associated with the development of type 2 diabetes mellitus
(T2DM). It is thus of clinical relevance to identify plasma biomarkers of mitochondrial …
(T2DM). It is thus of clinical relevance to identify plasma biomarkers of mitochondrial …